Apart from several vascular lesions, CCM3 malfunction can also induce abnormal activation of β-catenin and a range of downstream oncogenic signalling pathways [30,31], facilitating endothelial–mesenchymal transition (EMT) involved in several steps of cancer progression. This evidence concerns the gene PDCD10 and cancer.